7 n9 k( n, l# M4 O! p" }$ \2 p8 F
麻烦大叔告诉我第三个的理由是什么?
6 D' l3 l. I$ U0 H7 \, d! H& }7 E; W
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:# z+ ~/ _/ s& S5 N5 `! }7 {% p% l _4 M
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.7 o$ B( j! Q! n0 n& ` http://www.ncbi.nlm.nih.gov/pubmed/22968184 / M: }7 L! E: y# b) r 8 X8 |8 S- j$ v h. `# V依维莫司联合吉非替尼抑制非小细胞肺癌细胞系的效果和作用机制9 V5 G+ ~1 y, t" V/ @9 f$ v http://d.wanfangdata.com.cn/Thesis_Y1770447.aspx